Expression of p65, DD3 and c-erbB2 genes in prostate cancer

Neoplasma

Volumn 50, Issue 2, 2003, Pages 97-101

  Balcerczak, E ^a   Mirowski, M ^a   Sasor, A ^b   Wierzbicki, R ^a  

^a Dept of Pharmaceutical Biochemistry   (Poland)

^b Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego   (Poland)

Author keywords

c erbB2; DD3; p65; PCR; Prostate cancer; RT PCR

Indexed keywords

SYNAPTOTAGMIN;

ARTICLE; CANCER GRADING; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; ONCOGENE; ONCOGENE C ERB; ONCOGENE DD3; ONCOGENE P65; PROSTATE CARCINOMA; TUMOR DIFFERENTIATION;

EID: 0038328896     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. BALCERCZAK E, KUPNICKA D, NIEWIADOMSKA H, BARTKOWIAK J, MIROWSKI M. p65 gene expression and c-erbB2 gene amplification in breast cancers. Folia Histochem Cytobiol 2001; 39: 32-33.
2. BUSSEMAKERS MJG, VAN BOKHOVEN A, VERHAEGH GW, SMITH FP, KARTHAUS HFM, SCHALKEN JA, DEBRUYNE FMJ, RU N, ISAACS WB. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-5979.
3. CHIARODO A. National Cancer Institute roundtable on prostate cancer; future research directions. Cancer Res 1991; 51: 2498-2505.
4. CHOMCZYŃSKI P, SACCHI N. Single-step method of RNA isolation by acid guanidinum thiocynate-phenol-chloroform extraction. Analytical Biochem 1987; 162: 156-159.
5. FOURNIER G, LATIL A, AMET Y, ABALAIN JH, VOLANT A, MANGIN P, FLOCH HH, LIDEREAU R. Gen amplifications in advanced-stage human prostate cancer. Urol Res 1995; 22: 343-347.
6. HANAUSEK M, MIROWSKI M, WALASZEK Z, WANG S, KROKOS C, SORIANO TF. A new tumor marker (p65) aids in the accurate detection of prostate cancer. Proc Am Assoc Cancer Res 1994; 35: 233.
7. HANAUSEK M, SZEMRAJ J, ADAMS AK, WALASZEK Z. The oncofetal protein p65: a new member of the steroid/thyroid receptor superfamily. Cancer Detect Prevent 1996; 20: 1-8.
8. ISRAELI RS, GROB M, TAIR WR. Prostate-specific membrane antigen and other prostatic tumor markers on the horizon. Urol Clin North Am 1997; 24: 439-450.
9. LATIL A, BIECHE I, VIDAUD D, LIDEREAU R, BERTHON P, VIDAUD M. Evaluation of androgen, estrogen (ER alpha and ER beta) and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcriptionpolymerase chain reaction assays. Cancer Res 2001; 61: 1919-1926.
10. LEAV I, LAU KM, ADAMS JY, McNEAL JE, TAPLIN ME, WANG J, SINGH H, HO SM. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001; 159: 79-92.
11. MIROWSKI M, SHERMAN U, HANAUSEK M. Purification and characterization of a 65 kDa tumor-associated phosphoprotein from rat transplantable hepatocellular carcinoma 1682C cell line. Prot Expr Purif 1992; 3: 196-203.
12. MIROWSKI M, WALASZEK Z, SHERMAN U, HANAUSEK M. Comparative structural analysis of human and rat 65 kDa tumor-associated phosphoproteins. Int J Biochem 1993; 25: 1865-1871.
13. MIROWSKI M, BŁOŃSKI JE, NIEWIADOMSKA H, OLBORSKI B, WALASZEK Z, HANAUSEK M, WOZNIAK L. Immunohistochemical study of 65-kDa oncofetal protein expression in breast cancer. The Breast 1997; 6: 284-290.
14. NIEWIADOMSKA H, MIROWSKI M, BARTKOWIAK J, STEMPIEN M, BLONSKI JZ, WALASZEK Z, WIERZBICKI R, HANAUSEK M. Oestrogen/progesterone receptors and 65 kDa tumor-associated phosphoprotein (p65) expression in breast cancer patients. Biomed Lett 1997; 56: 91-99.
15. NIEWIADOMSKA H, MIROWSKI M, STEMPIEN M, BŁOŃSKI JZ, CZYZ W, SWITALSKA J, MATYGA E, HANAUSEK M, WIERZBICKI R. Immunohistochemical analysis of expression of a 65 kDa oncofetal protein (p65), epidermal growth factor receptor (EGFR), oncogene c-erbB2 and tumor suppressor gene p53 protein products in breast cancer patients. Neoplasma 2000; 1: 8-14.
16. PARKER SL, TONG T, BOLDEN S, WINGO PA. Cancer statistics. CA Cancer J Clin 1997; 47: 5-27.
17. REITER RE, ZHENNEN G, WATABE T, THOMAS G, SZIGETI K, DAVIS E, WAHL M, NISITANI S, YAMASHIRO J, LE BEAU MM, LODA M, WITTE ON. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998; 95: 1735-1740.
18. Ross JS, NAZEER T, CHURCH K, AMATO C, FIGGE H, RIFKIN MD, FISHER HA. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer 1993; 72: 3020-3028.
19. SCHWARTZ S, CACERES C, MOROTE J, DE TORES I, RODRIGUEZ-VALLEJO J, GONZALEZ J. Over-expression of epidermal growth factor receptor and c-erbB2/neu but not of int-2 genes in benign prostatic hyperplasia by means of semi-quantitative PCR. Int J Cancer 1998; 76: 464-467.
20. SKACEL M, ORMSBY AH, PETTAY JD, TSIFTSAKIS EK, LIOU LS, KLEIN EA, LEVIN HS, ZIPPE CD, TUBBS RR. Aneusomy of chromosomes 7, 8 and 17 and amplification of Her-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray. Hum Pathol 2001; 32: 1392-1397.
21. SOKOLL LJ, CHAN DW. Prostate-specific antigen: its discovery and biochemical characteristics. Urol Clin North Am 1997; 24: 253-259.
22. TOKUNAGA K, TANIGUCHI H, YODA K, SHIMIZU M, SAKIYAMA S. Nucleotide sequence of a full-length cDNA for mouse cytoskeletal β-actin mRNA. Nucleic Acid Res 1986; 14: 2829-2836.
23. VERHAEGH GW, VAN BOKHOVEN A, SMITH F, SCHALKEN JA, BUSSEMAKERS MJG. Isolation and characterization of the promoter of the human prostate-cancer-specific DD3 gene. J Biol Chem 2000; 275: 37496-37503.
24. WARE JI, MAYGARDEN SJ, KOONTZ WW JR, STROM SC. Immunohistochemical detection of c-ErbB2 protein in human benign and neoplastic prostate. Hum Pathol 1991; 22: 254-258.